SlideShare une entreprise Scribd logo
1  sur  16
CISPLATIN Terry Clayton Biological Inorganic Chemistry April 1, 2007
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object]
Discovery ,[object Object],[object Object],[object Object],Nature   205 , 698 - 699 (13 February 1965); doi:10.1038/205698a0  Inhibition of Cell Division in  Escherichia coli  by Electrolysis Products from a Platinum Electrode BARNETT ROSENBERG, LORETTA VAN CAMP & THOMAS KRIGAS Biophysics Department, Michigan State University, East Lansing.
Chemotherapeutic agents for Oncology ,[object Object],[object Object],[object Object],[object Object]
Results! ,[object Object],[object Object],[object Object],J. Med. Chem. 2004, 47, 761-763. ,[object Object],[object Object],[object Object],[object Object],[object Object],Side Effects Nature, 1969, 222, 385-387.
Cisplatin Synthesis Dhara, S.C., A Rapid Method for the Synthesis of cis-[Pt(NH3)2Cl2], Indian Journal of Chemistry, vol. 8, No. 2, Feb. 1970, pp. 193-194.
F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site",  Nucleic Acids Res , 1999,  27 , 1837
Structural Requirement ,[object Object],[object Object],[object Object],Reedijk (2003) Proc. Natl. Acad. Sci. USA, 100.(7), 3611-3616.
Sites for Pt binding J. Chem. Ed. 83, 5, 2006 ,[object Object],[object Object]
Mechanism? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],J. Am. Chem. Soc. 2001, 123, 3171-3172 J. Am. Chem. Soc. 2005, 127, 12768-12769
Why not trans? ,[object Object],[object Object],[object Object],[object Object],1:  Eur J Cancer. 1997 Oct;33(11):1823-8  ,[object Object],[object Object]
Analogues ,[object Object],Carboplatin Oxaliplatin Nedaplatin ,[object Object],[object Object]
Future ,[object Object],[object Object],[object Object],Bis(aceto)(1-adamantylamine)aminedichloroplatinum J. Med. Chem., 2004, 47, 761-763
Cytotoxicity Cisplatin-Resistant Tumor Lines   IC 50  ( µM) Cancer cell line cisplatin 1 Chronic myelogenous leukemia K562 >80 3 Chronic myelogenous leukemia KG-1 48 2 Acute myelogenous leukemia ML-2 >80 1 Mouse melanoma  B16 >80 6 Colon cancer HT-29N >80 12 Colon cancer HT29 50 8 Colon cancer HCT116 >80 9 Lung carcinoma A427 63 6 Breast carcinoma HBL100 63 6 Breast carcinoma MCF-7 71 8 Lung carcinoma CORL23/CTR >80 25 Ovarian carcinoma A2780 4 4 Ovarian carcinoma A2780/cis 40 3 Ovarian carcinoma A2780/cis90 >80 7
Questions
Thank You

Contenu connexe

Tendances

Reserpine structural elucidation
Reserpine structural elucidationReserpine structural elucidation
Reserpine structural elucidationDrSSreenivasa
 
Allyl derivatives, sandwich compounds and half sandwich compounds
Allyl derivatives, sandwich compounds and half sandwich compoundsAllyl derivatives, sandwich compounds and half sandwich compounds
Allyl derivatives, sandwich compounds and half sandwich compoundsVijayalakshmiNair1
 
Alkylating agents and antimetabolites
Alkylating agents and antimetabolitesAlkylating agents and antimetabolites
Alkylating agents and antimetabolitesGedion Yilma
 
Introduction to chemotherapy of cancer
Introduction to chemotherapy of cancerIntroduction to chemotherapy of cancer
Introduction to chemotherapy of cancerSubramani Parasuraman
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extraNilesh Kucha
 
Recent advances in Cancer Chemotherapy
Recent advances in Cancer ChemotherapyRecent advances in Cancer Chemotherapy
Recent advances in Cancer ChemotherapyDr. Kunal Chitnis
 
CHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptx
CHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptxCHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptx
CHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptxMZzaddy
 
Steric parameters taft’s steric factor (es)
Steric parameters  taft’s steric factor (es)Steric parameters  taft’s steric factor (es)
Steric parameters taft’s steric factor (es)Shikha Popali
 
Protecting Groups In Organic Synthesis
Protecting Groups In Organic SynthesisProtecting Groups In Organic Synthesis
Protecting Groups In Organic SynthesisApoorv Rastogi
 
Ruthenium role in cancer therapy
Ruthenium role in cancer therapy Ruthenium role in cancer therapy
Ruthenium role in cancer therapy Fari Ba
 
Nonclassical Carbocation
Nonclassical CarbocationNonclassical Carbocation
Nonclassical CarbocationPallavi Pradhan
 
Metal cyclopentadiene complexes
Metal  cyclopentadiene complexesMetal  cyclopentadiene complexes
Metal cyclopentadiene complexesDrGeetaTewari
 
Retrosynthes analysis and disconnection approach
Retrosynthes analysis and disconnection approach Retrosynthes analysis and disconnection approach
Retrosynthes analysis and disconnection approach ProttayDutta1
 

Tendances (20)

Reserpine structural elucidation
Reserpine structural elucidationReserpine structural elucidation
Reserpine structural elucidation
 
Allyl derivatives, sandwich compounds and half sandwich compounds
Allyl derivatives, sandwich compounds and half sandwich compoundsAllyl derivatives, sandwich compounds and half sandwich compounds
Allyl derivatives, sandwich compounds and half sandwich compounds
 
TAXANES AND PODOPHYLLOTOXINS
TAXANES AND PODOPHYLLOTOXINSTAXANES AND PODOPHYLLOTOXINS
TAXANES AND PODOPHYLLOTOXINS
 
Platinum agents
Platinum agentsPlatinum agents
Platinum agents
 
Pcc cromates .
Pcc cromates   .Pcc cromates   .
Pcc cromates .
 
Chiral auxiliary!
Chiral auxiliary!Chiral auxiliary!
Chiral auxiliary!
 
Alkylating agents and antimetabolites
Alkylating agents and antimetabolitesAlkylating agents and antimetabolites
Alkylating agents and antimetabolites
 
Introduction to chemotherapy of cancer
Introduction to chemotherapy of cancerIntroduction to chemotherapy of cancer
Introduction to chemotherapy of cancer
 
Chapter 20 alkylating agent extra
Chapter 20  alkylating agent extraChapter 20  alkylating agent extra
Chapter 20 alkylating agent extra
 
Recent advances in Cancer Chemotherapy
Recent advances in Cancer ChemotherapyRecent advances in Cancer Chemotherapy
Recent advances in Cancer Chemotherapy
 
CHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptx
CHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptxCHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptx
CHEMISTRY OF PACLITAXEL( NATURAL CHEMISTRY).pptx
 
Photochemistry of alkenes
Photochemistry of alkenesPhotochemistry of alkenes
Photochemistry of alkenes
 
Carcinogenesis
CarcinogenesisCarcinogenesis
Carcinogenesis
 
Steric parameters taft’s steric factor (es)
Steric parameters  taft’s steric factor (es)Steric parameters  taft’s steric factor (es)
Steric parameters taft’s steric factor (es)
 
Protecting Groups In Organic Synthesis
Protecting Groups In Organic SynthesisProtecting Groups In Organic Synthesis
Protecting Groups In Organic Synthesis
 
Ruthenium role in cancer therapy
Ruthenium role in cancer therapy Ruthenium role in cancer therapy
Ruthenium role in cancer therapy
 
Nonclassical Carbocation
Nonclassical CarbocationNonclassical Carbocation
Nonclassical Carbocation
 
Metal cyclopentadiene complexes
Metal  cyclopentadiene complexesMetal  cyclopentadiene complexes
Metal cyclopentadiene complexes
 
Retrosynthes analysis and disconnection approach
Retrosynthes analysis and disconnection approach Retrosynthes analysis and disconnection approach
Retrosynthes analysis and disconnection approach
 
Dept nmr
Dept nmrDept nmr
Dept nmr
 

Similaire à Cisplatin

Cancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsCancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsMaryam Yekefallah
 
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursMCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursEuropean School of Oncology
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMohamed Abdulla
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Mohamed Abdulla
 
New developments of targeted therapy in nsclc
New developments of targeted therapy in nsclcNew developments of targeted therapy in nsclc
New developments of targeted therapy in nsclclihua jiao
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerAlok Gupta
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppttttran
 
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid LeukemiaPresent and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemialarriva
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...isrodoy isr
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoMauricio Lema
 
Gastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxGastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxSujan Shrestha
 

Similaire à Cisplatin (20)

CRPC management
CRPC managementCRPC management
CRPC management
 
Cancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materialsCancer Cells and anticancer effect of some plants and materials
Cancer Cells and anticancer effect of some plants and materials
 
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumoursMCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
MCO 2011 - Slide 30 - K. Öberg - Spotlight session - Neuroendocrine tumours
 
targeted therapy
targeted therapytargeted therapy
targeted therapy
 
Metastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insightMetastatic bone disease: An old dogma and a new insight
Metastatic bone disease: An old dogma and a new insight
 
Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019Neuroendocrine Tumors in 2019
Neuroendocrine Tumors in 2019
 
Dr. Goy MCL
Dr. Goy MCLDr. Goy MCL
Dr. Goy MCL
 
New developments of targeted therapy in nsclc
New developments of targeted therapy in nsclcNew developments of targeted therapy in nsclc
New developments of targeted therapy in nsclc
 
Targeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancerTargeted therapy and immunotherapy in lung cancer
Targeted therapy and immunotherapy in lung cancer
 
5943408.ppt
5943408.ppt5943408.ppt
5943408.ppt
 
7 capdevila
7 capdevila7 capdevila
7 capdevila
 
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
Gene Profiling in Clinical Oncology - Slide 4 - L. Lacroix - New markers to d...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid LeukemiaPresent and Future Impact of Cytogenetics on Acute Myeloid Leukemia
Present and Future Impact of Cytogenetics on Acute Myeloid Leukemia
 
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
4 ΣΥΜΠΟΣΙΟ ΚΛΙΝΙΚΗΣ ΟΓΚΟΛΟΓΙΑΣ ΡΟΔΟΥ: Εξελίξεις στη θεραπεία του πλακώδους κα...
 
Prostate cancer
Prostate cancer   Prostate cancer
Prostate cancer
 
PhD
PhDPhD
PhD
 
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásicoActualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
Actualización en el abordaje terapéutico ante un cáncer colorrectal metastásico
 
Prostate 101
Prostate 101Prostate 101
Prostate 101
 
Gastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptxGastrointestinal stromal tumors (GIST).pptx
Gastrointestinal stromal tumors (GIST).pptx
 

Cisplatin

  • 1. CISPLATIN Terry Clayton Biological Inorganic Chemistry April 1, 2007
  • 2.
  • 3.
  • 4.
  • 5.
  • 6. Cisplatin Synthesis Dhara, S.C., A Rapid Method for the Synthesis of cis-[Pt(NH3)2Cl2], Indian Journal of Chemistry, vol. 8, No. 2, Feb. 1970, pp. 193-194.
  • 7. F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site", Nucleic Acids Res , 1999, 27 , 1837
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14. Cytotoxicity Cisplatin-Resistant Tumor Lines IC 50 ( µM) Cancer cell line cisplatin 1 Chronic myelogenous leukemia K562 >80 3 Chronic myelogenous leukemia KG-1 48 2 Acute myelogenous leukemia ML-2 >80 1 Mouse melanoma B16 >80 6 Colon cancer HT-29N >80 12 Colon cancer HT29 50 8 Colon cancer HCT116 >80 9 Lung carcinoma A427 63 6 Breast carcinoma HBL100 63 6 Breast carcinoma MCF-7 71 8 Lung carcinoma CORL23/CTR >80 25 Ovarian carcinoma A2780 4 4 Ovarian carcinoma A2780/cis 40 3 Ovarian carcinoma A2780/cis90 >80 7

Notes de l'éditeur

  1. While studying electric fields and growth of E. Coli/// Rosenberg 1964 Group VIIIb transition metal compounds inhibit cell division 1-10ppm Growth not affected Components of the experimental medium were electrolyzed and tested for the presence of oxidizing agents by reacting with KI/starch solutions. Positive results were found for NH4Cl. NH4)2PtCl6 was formed to be the active agent.
  2. the trans effect is the labilization of ligands trans to certain other ligands, which can thus be regarded as trans directing ligands.
  3. F. Coste, J. M. Malinge, L. Serre, W. Shepard, M. Roth, M. Leng and C. Zelwer, "Crystal structure of a double-stranded DNA containing a cisplatin interstrand cross-link at 1.63 A resolution: hydration at the platinated site", Nucleic Acids Res , 1999, 27 , 1837
  4. Preformed Pt- HSA (human serum albumin) administered clinically to patients there was increased survival time. Individuals with low HSA did not respond well to cisplatin Centerwall at Syracuse found using HSQC NMR N15 NMR-h1
  5. Carboplatin cyclobutane dicarboxylate decreases reactivity. Oxaliplatin for colon cancer…oxalate increases water solubility…othermechanisms unknown
  6. Many insecticides show cross resistance Increased reactivity with glutathione may reduce cytotoxicity
  7. Lead compound in future studies of Pt. compounds with hydrophobic ligands. They speculate that the structure of water molecules around adamantineamine affect reaction with glutathione and thiols.